Search

everythinglearnresearchcommunity

for

Search:↓

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Blocking JAK-STAT signaling can lead to hair growth.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

A new microneedle patch effectively promotes hair regrowth with less frequent dosing.

JAK inhibitors are effective treatments for alopecia areata.

New and repurposed treatments are improving outcomes in dermatology.

Kaempferol promotes hair growth and could be a natural treatment for hair loss.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

New treatments show promise for hair loss, especially JAK inhibitors for alopecia areata.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Topical JAK inhibitors may help treat some skin conditions but need more research.